Raw Material Receipt: GMP Receiving, Quarantine and Release

Raw Material Receipt is the controlled intake of incoming manufacturing materials, including shipment identification, condition examination, receipt recording and entry into quarantine pending evaluation and an authorised decision on use. This is an operational definition, not a universal legal definition.

Receipt connects the delivery at the dock to an identifiable material record and a controlled holding status. Its boundary is the handoff for evaluation: receiving establishes what arrived and its apparent condition; it does not itself establish suitability for manufacturing.

The scope here includes incoming manufacturing components and the handoffs needed to establish their use status. Receipt of returned finished products, supplier qualification and sampling-plan design are separate activities. For decisions about sample numbers, container selection or sampling methods, see raw-material sampling. The comparison above separates operational responsibilities; it is not a prescribed sequence for every product or site.

Start with the intended product, the material’s function and the destination market—not the supplier’s material name alone. As an applicability-screening practice, ask what the site will manufacture, how the received material will be used and which jurisdiction governs that activity. A shared ingredient name is not a sufficient basis for assigning the same receiving requirements.

For drug-material quarantine storage, 21 CFR 211.82(b) directs storage within the area to § 211.80. Check the current text of § 211.80 for those requirements; detailed storage controls are outside this scope map.

Keep the authority labels separate

• Binding law: the cited CFR provisions, applied within their product and activity scope.
• Official guidance: identify recommendations separately from regulatory obligations; do not describe guidance as CFR wording.
• Recognised industry practice: site-selected identifiers, workflow states and interface controls are operational design choices, not prescribed CFR terminology.
• Software support: distinguish recordkeeping and workflow assistance from the applicable legal requirements and the human approval decision.

Use the broader drug GMP framework or dietary-supplement GMP framework to orient the site’s applicability review. For the supplement identity branch, see component identity confirmation. The checklist, quarantine and identity sections address the operating details; this map identifies which regulatory branch to examine first.

Use the following as a risk-based operating checklist, not a universal legal specification. The documents required, inspection extent and acceptance criteria should reflect the material and the site's written receiving procedures.

1. Match the delivery. Compare the purchase-order line, material code, supplier, declared manufacturer where relevant, supplier lot, container count and quantity units against the delivery documents and container labels. Resolve ambiguous descriptions against controlled material master data, rather than accepting a familiar trade name as a sufficient match. Keep ordered, declared and physically received quantities distinguishable.
2. Examine external condition and seals. Look for damaged containers, leakage, contamination, unreadable labels and missing or broken seals. Record which containers are affected rather than describing the entire delivery simply as “damaged.” For U.S. drug components, 21 CFR 211.82(a) requires visual examination of each container or grouping upon receipt and before acceptance for content labeling, damage or broken seals, and contamination.
3. Review the relevant documents and transport evidence. Compare transport records with the site's material-specific requirements, including temperature records where required by the receiving procedure. Missing evidence should become an unresolved observation, not an assumed pass. Keep product categories distinct: for dietary-supplement packaging and labels—not components—21 CFR 111.160(b)) requires visual examination of the supplier's invoice, guarantee or certification to ensure consistency with the purchase order.
4. Identify the physical receipt. Preserve the supplier-lot identifier while assigning a separate receipt identifier to each delivery and container identifiers at the site's chosen handling level. Record count, mass or volume with explicit units. Label quantities as declared or measured; do not silently replace one with the other. Where weighing is used, keep the quantity basis clear through net-versus-gross reconciliation.
5. Keep repeat deliveries visible. For U.S. drug materials within its scope, 21 CFR 211.84(b) requires representative samples of each shipment of each lot. The receiving implication is that a later shipment bearing the same supplier-lot number must remain distinguishable for the sampling workflow; do not merge it into an earlier receipt simply because the lot identifier matches. Container selection and sample quantities belong in the sampling procedure.
6. Record exceptions before normal put-away. Open a receiving discrepancy for mismatches, damage or missing required information, identifying the affected receipt or containers and assigning an owner. Link photographs, seal observations and transport records to those identifiers rather than leaving them as detached attachments.

Close the dock transaction with a defined custodian, recorded storage location and protected material status. The handover should make every unresolved discrepancy and its owner visible to the next person handling the stock.

Receiving material into stock establishes custody, not permission to use it. Keep physical receipt, evaluation and the authorised disposition as separate events.

Binding U.S. requirements

For drug components, containers and closures, 21 CFR 211.82(b) requires storage under quarantine pending appropriate testing or examination and release. Under 21 CFR 211.84(a), each lot remains withheld from use until the applicable sampling, testing or examination and release by the quality control unit. Lots that fail the specified requirements must be rejected under 21 CFR 211.84(e).

For dietary-supplement components, 21 CFR 111.155(c)) establishes quarantine before use until its conditions are satisfied. Quality control personnel’s approval for use is a distinct condition under 21 CFR 111.155(c)(3)(3)); recording receipt does not substitute for that approval.

Operating model: three independent controls

Conceptual workflow: receipt → quarantine → evaluation → explicitly scoped human disposition → execution of that decision. This is a site-designed operating model, not prescribed regulatory wording. A warehouse move or quantity adjustment should not independently change quarantine status.

Before approval, make the proposed scope visible: material identity, lot, affected delivery and container identifiers, quantity, supporting evaluation and unresolved exceptions. Use container status tracking to distinguish affected units without treating the remaining undamaged count as releasable stock. Any narrower proposed disposition needs an explicit justification and authorised decision; it must not bypass a lot-level rejection requirement.

Record who decided, what material the decision covers and when it takes effect. Software may enforce the resulting status, but human review and release remain separate from inventory posting.

A useful receiving record distinguishes the supplier’s lot from the delivery event and the containers actually handled. This lets reviewers reconstruct what arrived, which evidence applies and what material a decision covers.

Legally specified documentation for supplements

For dietary-supplement operations under 21 CFR Part 111, the receiving documentation requirements include:

• The receipt date, under 111.180(b)(3)(ii)(A)(3)(ii)(A)).
• The initials of the person performing the required operation, under 111.180(b)(3)(ii)(B)(3)(ii)(B)).
• Results of any tests or examinations conducted on components, under 111.180(b)(3)(ii)(C)(3)(ii)(C)).
• Any material review and disposition decision, under 111.180(b)(3)(ii)(D)(3)(ii)(D)).

Practical record relationships

The following relationship map is an industry-practice design aid. Its field names are illustrative, not a regulatory schema or a V5 data model.

Do not rely on a supplier lot number alone to establish evidence coverage. For split deliveries, explicitly associate each observation with its receipt and identify which receipts or containers the review assessed. A shared lot identifier does not explain whether an observation concerns the first delivery, the second or both.

Operational detail and preserved history

Additional operational records can include purchase-order references, quantities and units, condition observations, transport evidence, supplier certificates, exception references and attachments. These support reconciliation; they are not presented here as a universal mandatory field list.

Apply data-integrity design principles: preserve who changed a record, when and why, rather than replacing the original observation without explanation. Keep corrections connected to the original entry so reviewers can follow the receiving history without guessing which version informed the decision.

For drug components, 21 CFR 211.84(d)(1) states that at least one test shall be conducted to verify the identity of each component of a drug product, and that specific identity tests, if they exist, shall be used. Under 211.84(d)(2), each component shall be tested for conformity with all appropriate written specifications for purity, strength and quality; in lieu of that testing a supplier’s report of analysis may be accepted, provided that the manufacturer conducts at least one specific identity test on the component and establishes the reliability of the supplier’s analyses through appropriate validation of the supplier’s test results at appropriate intervals. A certificate therefore never replaces the manufacturer’s own identity test for a drug component. The supplement-side identity rules are separate and are covered on the component identity page.

Identity asks whether the material is what it is represented to be. Conformance evaluates the relevant acceptance criteria as a whole. A successful result answers the question addressed by that test; it does not settle every receiving or material-quality question. Keep the identity conclusion distinct from the overall acceptance decision.

For dietary ingredients, apply the identity requirement covered above: at least one appropriate test or examination. The exception in 21 CFR 111.75(a)(1)(i)(1)(i)) depends on both a petition and an agency exemption. A pending request is not an exemption. See component identity confirmation for that specific decision.

For drug components, 21 CFR 211.84(e) links approval and release for use to meeting the appropriate written specifications for identity, strength, quality and purity, and the related paragraph (d) tests. Identity alone is therefore not the complete acceptance basis.

Treat a supplier certificate as an evidence item: assess its material identity, lot reference, results and relevance to the applicable specification. Receiving the document is not an unqualified certificate-only acceptance route. Check the current text of 21 CFR 211.84(d) before adopting a drug-component testing or supplier-analysis acceptance strategy.

Example: assume a powder passes its identity test, but its drum liner is torn and moisture exposure remains unresolved. The result supports identity, not an absence of moisture damage. Keep the condition concern open for assessment rather than letting the passing result close it.

Use this practical decision-evidence checklist, with unresolved issues visible during exception-based review:

• Applicable specification version: which acceptance criteria govern?
• Required evidence: what tests, examinations and documents address those criteria?
• Reviewed results: what conclusions does each result support?
• Unresolved exceptions: what remains unknown or unacceptable?
• Authorised disposition: who made the decision, and on what basis?

An illustrative integration pattern assigns purchasing the order and material references, warehouse records the physical units and locations, and laboratory records the reviewed results. A designated quality process controls disposition. Define an owner for each shared field, which systems may update it, and how corrections propagate; do not let several systems independently overwrite quality status. These are implementation practices, not claims about V5 functionality. For laboratory handoffs, see MES to LIMS integration.

For duplicate receipt messages, retain a stable transaction identifier across retries. Compare the intended receipt quantity with physical stock and posted transactions before correcting a duplicate through a traceable adjustment. Record which posting was reversed and why. A technical retry should neither create another delivery event nor change the material’s quality decision; a successful message acknowledgement is not a new receipt.

For missing documents, wrong-lot results, unreadable labels or contradictory statuses, identify the affected stock, preserve the original evidence and assign an exception owner. Resume processing only through the site’s reviewed recovery route. Never silently remap a laboratory result to a different receipt to clear an interface error. Link the correction to the original receiving discrepancy so reviewers can follow the change.

During outages and external-laboratory handovers, preserve receipt and sample identifiers in temporary records. Before closing the incident, reconcile returned results, stock movements and disposition decisions against those identifiers. Apply the human disposition boundary covered above: restoring connectivity does not replace the reviewed decision.

Use these industry-practice scenarios to challenge receiving controls, not to rank incident frequency. Each check should leave evidence that a reviewer can inspect without relying on the receiver’s memory.

A clerical correction is appropriate when reliable original records establish what was entered incorrectly. An unreadable lot label or evidence of damaged packaging instead raises uncertainty about material identity or condition. Escalate that uncertainty for quality assessment; do not resolve it by choosing the most convenient value.

Keep the original entry, corrected value, reason, person and timing available for reconstruction. Include unresolved conflicts in exception-based review, with an owner and documented closure.

Case 1: Damaged seal on a U.S. drug-component delivery

Assume 24 drums arrive with a declared net content of 25 kg each: 24 × 25 kg = 600 kg. One drum has a damaged seal. The 23 intact drums represent 575 kg; the affected drum represents 25 kg. These are declared quantities, not independently verified weights.

Record the affected drum’s container identifier against the receipt and supplier lot, describe the seal damage, and escalate it to the quality control unit. Assume evaluation remains incomplete: applying the quarantine controls covered above, all 600 kg remains unavailable. Keep the damaged unit distinguishable during evaluation. Its identification narrows the location of the observed defect; it does not establish that the other 575 kg is suitable for use. Intact appearance alone does not support a partial-lot release decision.

Case 2: Passing assay, incomplete dietary-ingredient identity

Assume a U.S. supplement manufacturer receives 12 sacks at 20 kg each: 12 × 20 kg = 240 kg. An assay meets the site’s stated acceptance criterion, but identity verification remains incomplete and no agency exemption applies. No particular test method or numerical acceptance limit is assumed.

Apply the identity distinction covered above: keep the 240 kg in the pending-review workflow. The missing evidence is completed, documented component identity confirmation, not another copy of the passing assay. In this scenario, the laboratory owns completion of that evidence and designated quality control personnel own the acceptance decision. Record the outstanding item and its owner so that a passing assay does not silently close the receipt review.

Case 3: Split food-ingredient deliveries and a duplicate posting

Under an assumed food-site procedure, one supplier lot arrives in two deliveries: 40 bags × 25 kg = 1,000 kg, then 32 bags × 25 kg = 800 kg. The genuine total is 72 bags and 1,800 kg. Posting the second delivery twice produces 1,000 + 800 + 800 = 2,600 kg: an 800 kg overstatement.

Document the duplicate correction and preserve both genuine receipt records, including their separate delivery identifiers. Retain their shared supplier-lot relationship for bin-level lot genealogy. Reconcile inventory to 1,800 kg without merging the receipts or overwriting their histories. Keep each receipt’s quality status separate from the quantity repair: correcting the ledger is not a disposition decision.

Use this practical checklist at implementation and during periodic review. It tests operational traceability rather than establishing additional statutory duties.

• Define the product, intended use and jurisdiction covered by the receiving procedure.
• Assign receiving and quality responsibilities, including deputies for unavailable decision-makers.
• Establish identifier rules linking supplier lots, separate deliveries, containers and samples.
• Specify quantity units, conversion factors and how discrepancies are resolved.
• Map who owns each status change and where the authoritative status is recorded.
• Define exception routes and the evidence needed for each acceptance, rejection or continued-hold decision.

Walk one normal receipt and one exception receipt from supplier label through warehouse location, sample, reviewed result and disposition, then trace any issued material to its use. Include a later delivery of the same supplier lot: check that the shared lot pedigree does not obscure delivery-specific evidence. Include a record correction and follow its audit trail to test whether the revised information remains connected to the affected decision. Test relationships, not merely whether forms exist.

Can a reviewer reconstruct what arrived, what was observed, which evidence applied, who decided, what quantity was affected and which stock became available? Record unresolved contradictions as review findings with named owners.

Choose local measures such as unresolved receipt age, missing-evidence counts and correction counts to identify bottlenecks. Define each measure consistently; avoid universal targets or speed incentives that encourage premature disposition.